AU2010286253A1 - Polyhydroxylated bile acids for treatment of biliary disorders - Google Patents

Polyhydroxylated bile acids for treatment of biliary disorders Download PDF

Info

Publication number
AU2010286253A1
AU2010286253A1 AU2010286253A AU2010286253A AU2010286253A1 AU 2010286253 A1 AU2010286253 A1 AU 2010286253A1 AU 2010286253 A AU2010286253 A AU 2010286253A AU 2010286253 A AU2010286253 A AU 2010286253A AU 2010286253 A1 AU2010286253 A1 AU 2010286253A1
Authority
AU
Australia
Prior art keywords
acid
tetrahydroxy
bile
cholan
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010286253A
Other languages
English (en)
Inventor
Victor Ling
Jonathan Ahab Sheps
Renxue Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2010286253A1 publication Critical patent/AU2010286253A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010286253A 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders Abandoned AU2010286253A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23675009P 2009-08-25 2009-08-25
US61/236,750 2009-08-25
PCT/CA2010/001338 WO2011022838A1 (en) 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders

Publications (1)

Publication Number Publication Date
AU2010286253A1 true AU2010286253A1 (en) 2012-04-19

Family

ID=43627124

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010286253A Abandoned AU2010286253A1 (en) 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders

Country Status (7)

Country Link
EP (1) EP2470553B1 (https=)
JP (1) JP5909774B2 (https=)
CN (1) CN102712672B (https=)
AU (1) AU2010286253A1 (https=)
BR (1) BR112012004284B8 (https=)
SG (1) SG178562A1 (https=)
WO (1) WO2011022838A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12491190B2 (en) 2019-08-23 2025-12-09 Shenzhen Yunhe Pharmaceutical Technology Partnership (Limited) Bile acid derivative, composition and application thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013041519A1 (en) 2011-09-19 2013-03-28 ETH Zürich, ETH Transfer Ror gamma modulators
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
SG11201503697TA (en) * 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
JP6556129B2 (ja) * 2013-08-01 2019-08-07 アメリカ合衆国 ファルネソイドｘ受容体の阻害剤及び医薬としての使用
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
KR102204406B1 (ko) * 2019-01-23 2021-01-18 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물
CN109762043B (zh) * 2019-03-06 2020-07-24 华南理工大学 鹅去氧胆酸及其制备方法
KR20250171471A (ko) 2019-05-10 2025-12-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 장 박테리아 담즙산 대사의 소분자 조정제
CN110548037B (zh) * 2019-09-24 2023-06-02 江西天元药业有限公司 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
CN113024624B (zh) * 2019-12-25 2024-09-10 上海科胜药物研发有限公司 一种去氧胆酸的合成方法
WO2022233398A1 (en) 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
CN115337312B (zh) * 2022-08-19 2025-06-03 金熊药业(珠海横琴)有限公司 胆酸复合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
RU2224523C2 (ru) * 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
WO2006116814A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
US20090232913A1 (en) * 2005-05-02 2009-09-17 Momir Mikov Composition for the Control of Cholesterol Levels
US20110263546A1 (en) * 2008-02-26 2011-10-27 Renxue Wang Polyhydroxylated Bile Acids for Treatment of Biliary Disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12491190B2 (en) 2019-08-23 2025-12-09 Shenzhen Yunhe Pharmaceutical Technology Partnership (Limited) Bile acid derivative, composition and application thereof

Also Published As

Publication number Publication date
WO2011022838A1 (en) 2011-03-03
EP2470553B1 (en) 2024-06-19
JP5909774B2 (ja) 2016-04-27
EP2470553A1 (en) 2012-07-04
BR112012004284B1 (pt) 2021-01-05
EP2470553A4 (en) 2013-02-20
JP2013502442A (ja) 2013-01-24
BR112012004284A2 (pt) 2017-06-13
EP2470553C0 (en) 2024-06-19
CN102712672B (zh) 2016-09-14
CN102712672A (zh) 2012-10-03
WO2011022838A8 (en) 2011-06-16
BR112012004284B8 (pt) 2021-05-25
SG178562A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
US10543220B2 (en) Polyhydroxylated bile acids for treatment of biliary disorders
EP2470553B1 (en) Polyhydroxylated bile acids for treatment of biliary disorders
CA2716922C (en) Polyhydroxylated bile acids for treatment of biliary disorders
Csanaky et al. Organic anion–transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2‐null mice
Setchell et al. Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency
Li et al. β‑glucan, a dectin‑1 ligand, promotes macrophage M1 polarization via NF‑κB/autophagy pathway
Wang et al. Fluorous‐tagged peptide nanoparticles ameliorate acute lung injury via lysosomal stabilization and inflammation inhibition in pulmonary macrophages
Yang et al. Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis
Carlton et al. Molecular basis of intrahepatic cholestasis
Zou et al. A minimalist multifunctional nano-prodrug for drug resistance reverse and integration with PD-L1 mAb for enhanced immunotherapy of hepatocellular carcinoma
EP2392335B1 (en) Use of 24-norUDCA
CN103536922B (zh) 酰基辅酶a:胆固醇酰基转移酶‑2抑制剂在抑制肝癌生长中的应用
EP1906972B1 (en) LPA2 receptor agonist for treating diarrhea
US8361999B2 (en) Methods of treating cholesterol gallstone disease with ezetimibe
HK1176622A (en) Polyhydroxylated bile acids for treatment of biliary disorders
Millet et al. Partial inhibition of proteasome activity enhances remyelination after cuprizone-induced demyelination
HK1176622B (en) Polyhydroxylated bile acids for treatment of biliary disorders
US20220227804A1 (en) Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist
Pan et al. Implications of Bile Acids Activated Receptors in non-infectious diarrhea
Martinefski et al. Relationship between Bile Acids and Coenzyme Q10
Zhang et al. Oral administration properties and physiological functions evaluation of extracellular vesicles derived from colostrum and mature milk
Truong Roles for Bile Transporters in the Pathogenesis and Treatment of Liver and Intestinal Diseases
Martinefski et al. Cholestasis: The Close Relationship between Bile Acids and Coenzyme Q10
DK059630 ABLATING L-FABP IN SCP-2/SCP-X NULL MICE IMPAIRS BILE ACID METABOLISM AND BILIARY 2 HDL-CHOLESTEROL SECRETION 3
Verkade et al. Articles in PresS. Am J Physiol Gastrointest Liver Physiol (November 8, 2012). doi: 10.1152/ajpgi. 00322.2012

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted